Trials / Completed
CompletedNCT00024544
Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
A Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of SB 240683 in Patients With Symptomatic Steroid-Naive Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Facet Biotech · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate an investigational medication to treat chronic asthma. The research is being conducted at 20 clinical research sites in the US and is open to both men and women ages 18 to 70 years. Participants in the study will have a number of visits to a research site over an 8-month period. All study-related care and medication is provided to qualified participants at no cost. This includes all visits, examinations and laboratory work.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anti-IL-4 monoclonal antibody (pascolizumab) |
Timeline
- Start date
- 2001-08-01
- Primary completion
- 2003-02-01
- Completion
- 2003-02-01
- First posted
- 2001-09-20
- Last updated
- 2012-03-07
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00024544. Inclusion in this directory is not an endorsement.